Zogenix to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5
Zogenix (NASDAQ: ZGNX) will report its Q2 2021 financial results and host a conference call on August 5, 2021, at 4:30 PM ET. The company focuses on developing therapies for rare diseases, including its approved drug FINTEPLA for Dravet syndrome. Zogenix is also advancing late-stage programs for Lennox-Gastaut syndrome and TK2 deficiency, along with a planned study for CDKL5 Deficiency Disorder. The call will provide insights into the company's financial performance and future strategies.
- Zogenix's FINTEPLA is FDA-approved for Dravet syndrome, indicating regulatory confidence.
- The company is advancing therapies in late-stage development for two additional rare diseases.
- None.
EMERYVILLE, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will report its financial results for the second quarter ended June 30, 2021 and host a corporate update conference call and webcast after the market close on Thursday, August 5, 2021, at 4:30 PM Eastern Time.
| Conference Call Details | |
| Thursday, August 5, at 4:30 PM Eastern Time / 1:30 PM Pacific Time | |
| Toll Free: | 800-347-6311 |
| International: | 323-994-2131 |
| Conference ID: | 6229003 |
| Webcast: | http://public.viavid.com/index.php?id=145894 |
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
CONTACTS:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
Trish McCall
Porter Novelli
+1 (805) 390-3279
trish.mcall@porternovelli.com
FAQ
When will Zogenix report its Q2 2021 financial results?
What therapies is Zogenix currently developing?
What time is the Zogenix conference call scheduled for?
What is FINTEPLA used for?
